Scinai Immunotherapeutics (SCNI) Cash from Financing Activities (2019 - 2026)
Scinai Immunotherapeutics (SCNI) posted Cash from Financing Activities of $11000.0 for Q1 2026, down 99.26% sequentially from $1.5 million in Q2 2025, and down 89.42% YoY from $104000.0 in Q1 2025.
Scinai Immunotherapeutics (SCNI) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $11000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 89.42% year-over-year to $11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 69.11% YoY) and the FY2025 annual result came in at $5.8 million, up 67.68% from the prior year.
- Cash from Financing Activities declined to $11000.0 in Q1 2026 per SCNI's latest filing, from $1.5 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $2.0 million in Q4 2024 and troughed at -$468000.0 in Q2 2022.
- A 4-year average of $570625.0 and a median of $58000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 12208.33% in 2025, down 92.68% in 2025.
- Over 4 years, Cash from Financing Activities stood at -$468000.0 in 2022, then surged by 527.35% to $2.0 million in 2024, then retreated by 26.15% to $1.5 million in 2025, then sank by 99.26% to $11000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $11000.0, $1.5 million, and $104000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Jun 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 104,000.00 |
| Mar 31, 2025 | 104,000.00 |
| Dec 31, 2024 | 2.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Jun 30, 2022 | -468,000.00 |
| Jun 30, 2022 | -468,000.00 |
| Dec 31, 2021 | 8.88 Mn |
| Dec 31, 2021 | 8.88 Mn |
| Sep 30, 2021 | -988,000.00 |
| Sep 30, 2021 | -988,000.00 |